Sleep bruxism bears several similarities to restless legs syndrome, and a link to changes in central dopamine activity has been considered in both conditions. The dopamine agonist pramipexole is currently indicated for the symptomatic treatment of restless legs. The effect of pramipexole on sleep bruxism was investigated in subjects with 'probable bruxism' recruited at the Orofacial Pain Clinic. Thirteen patients underwent polysomnographic recordings, including bilateral masseter electromyographic activity. Following habituation to the recording equipment, a baseline registration was used to confirm bruxism [total episodes per hour, mean 11.3 (6.3)]. Following randomisation, subjects received no treatment or pramipexole titrated from 0.09 to 0.54 mg, o.d., for 3 weeks according to a crossover procedure. A polysomnographic-electromyographic registration was performed at the end of each period. Pramipexole was associated with more frequent awakenings and a reduction in rapid eye movement sleep (both P ≤ 0.02). Sleep apnea decreased marginally after pramipexole (apnea-hypopnea index 17.1 compared with control 21.5, P ≤ 0.05). The number of bruxism episodes, phasic, tonic and mixed per hour, remained unchanged after pramipexole [total episodes per hour 12.7 (8.5) and 9.8 (5.2) during pramipexole and control conditions, respectively]. It is concluded, from this pilot study, that sleep bruxism is not affected by the dopaminergic agent, pramipexole.
IN TROD UCTI ON
Sleep bruxism (SB) is defined as a 'stereotyped movement disorder characterised by grinding or clenching of the teeth during sleep' (American Academy of Sleep Medicine, 2014; American Sleep Disorders Association, 1990) . A large survey reported sleep-related teeth grinding at least once a week in more than 8% of the general population (Ohayon et al., 2001) . The objective confirmation of SB requires overnight polysomnographic (PSG) and masticatory muscle electromyographic (EMG) recordings (Raphael et al., 2012) . A study using these methods, in a representative sample of the general population, reported a prevalence of SB in excess of 7% (Maluly et al., 2013) .
Sleep bruxism has been associated with several deleterious clinical consequences in dental and related structures (Klasser et al., 2010) , and bruxism is regarded as a risk factor for painful temporomandibular disorders (TMD; Fernandes et al., 2012) . There is no accepted single cure for SB, apart from strictly dental protective measures (Huynh et al., 2007; Klasser et al., 2010; Macedo et al., 2007) .
There is evidence suggesting that the autonomic nervous system plays a role in the genesis of SB (Kato et al., 2001; Lobbezoo and Naeije, 2001) . Some early studies linked central dopaminergic mechanisms and bruxism (De Laat and Macaluso, 2002; Lobbezoo and Naeije, 2001 ). However, pharmacological agents have not been systematically explored in SB with respect to either the amelioration or the exacerbation of the condition (Winocur et al., 2003) . Consequently, a recent systematic review concluded that there is insufficient evidence to support any established pharmacological treatment in SB (Macedo et al., 2014) .
Restless legs syndrome/Willis-Ekblom disease (RLS/ WED) is a neurological, sensorimotor disorder characterised by an urge to move the legs. Most affected patients experience involuntary, semi-rhythmic periodic limb movements (PLM) during sleep (Allen et al., 2003) . The sleeprelated incidence and repetitive occurrence of bruxism bears several similarities to PLM (Lavigne and Montplaisir, 1994; Van Der Zaag et al., 2014) , and responsiveness to dopaminergic agents in both conditions has been put forward as a possibility (Lobbezoo et al., 1997; Van Der Zaag et al., 2007) . The receptor agonist, pramipexole (PPX), provides a mainstay therapy in RLS/WED. However, the possible effect of dopamine-related drugs in SB has been insufficiently explored .
The current study evaluated the potential involvement of a dopamine-related dysfunction in SB. More specifically, we evaluated the effect of the dopamine agonist, PPX, on objectively assessed physiological markers of SB.
MATERI ALS AND METHODS

Subjects and study design
This was an open, randomised, two-period, crossover study comparing PPX and control conditions (no active treatment) in patients with bruxism.
Subjects were selected from a pool of patients attending the Department of Orofacial Pain, Sahlgrenska University Hospital/M€ olndal, Sweden. They all had severe SB based on self-reported symptoms and documented clinical signs. Long-lasting teeth grinding had been witnessed by a bed partner or others. Severe tooth wear, multiple fractures of teeth or restorations, signs of heavy grinding on oral appliances, teeth impressions on the lips or tongue, line alba in the cheeks, jaw muscle hypertrophy, and signs and symptoms of TMD occurred in various combinations. Fifty putative bruxers were invited, and given full and adequate verbal and written information about the study. Twenty-five of them declined participation. Five subjects fulfilled at least one exclusion criterion. Twenty subjects were finally included and informed consent was given by all study participants.
The inclusion criteria were presumed primary SB, i.e. not caused by any medical disorder or medication, female or male gender and age over 18 years, the presence of natural dentition, including fixed restorations, with at least one pair of occluding molars on each side, and the provision of informed consent prior to any study-specific procedures.
The exclusion criteria included women with child-bearing potential without an adequate method of contraception, breastfeeding women, and patients with pharmacological or dietary supplements that might significantly influence RLS/ WED symptoms. Details of the exclusion criteria are given in the supporting information.
The study protocol was reviewed and approved by the Regional Ethical Review Board, University of Gothenburg, Gothenburg, Sweden (dnr 451-10) and the Swedish Medical Products Agency (dnr 151:2010/65574).
Procedure
The detailed study flow is shown in Fig. 1 . Visit 1 included a physical examination. Demographic data, social status, medical/dental/sleep history and a specific history of bruxism were collected. Weight and height were recorded to the nearest kilo and centimetre, and body mass index (BMI) was calculated. A pregnancy test, if applicable, was administered. Vital signs, pulse, systolic and diastolic blood pressure after 5 min of rest in the supine position were recorded by the study nurse. Blood sampling (20 mL) was performed for haematology and clinical chemistry. Orofacial examinations were performed by one orofacial pain specialist dentist (B. J. C.). Clinical signs and symptoms were summarised in a temporomandibular index (TMI; Pehling et al., 2002) . A diagnosis according to the Research Diagnostic Criteria for TMD (RDC/TMD) axis 1 (Dworkin and LeResche, 1992) , as well as a score of the degree of dental abrasion (modified after Johansson et al., 1993) , were established.
The ambulatory PSG/EMG was recorded with an Embla â A10 system (Embla, Colorado, USA) applied by an experienced sleep technician at the sleep medicine unit. Recorded signals included electroencephalography (C3/A2, C4/A1, O1/ A2, F4/A1), electrooculography (right/left), EMG (submental, right and left masseter and tibial muscles) and electrocardiography. The masseter EMG electrodes were placed on the main bulk of the muscle according to a template generated for each patient. The recording also included a nasal pressure cannula, a thermistor, thoraco-abdominal respiratory effort belts, oximetry and body position (Kushida et al., 2005; Silber et al., 2007) . All PSG/EMG recordings (starting at approximately 22:00 hours) were performed in the patients' homes. Subjects returned to the study centre in the morning. The first night recording was made solely for habituation and the recorded data are not given. The three subsequent PSG/EMG recordings in the study were made in an identical manner.
Patient-reported outcome measures (PROMs) included the Swedish versions of eight self-administered questionnaires under standardised conditions in a quiet room in association with visits 2, 3 and 4. They included the International Restless Legs Syndrome Study Group (IRLS) standard to assess the severity of RLS/WED, the Epworth Sleepiness Scale (ESS), the Functional Outcomes of Sleep Questionnaire (FOSQ), the Insomnia Severity Index (ISI), the Karolinska Sleep Scale (KSS), the Pittsburgh Sleep Quality Index (PSQI), and the Sleep Scale from the Medical Outcome Study (MOS) for aspects of sleep. The Short-Form Health Survey-36 (SF-36) was used to assess patient-reported quality of life (for references, see supporting information).
Participants were randomised using a computer-generated sequence to start with medication with PPX or control conditions (CTR) immediately after the baseline registration (visit 2). Sealed, opaque envelopes were used by the study nurse in the allocation concealment. Medication was provided in the form of 0.18 mg PPX tablets (Pramipexole Bluefish Pharma â Stockholm, Sweden) to be taken daily, 2-3 h before bedtime. Up-titration in accordance with the manufacturer's recommendation was undertaken during a period of 3 weeks. A dose of 0.09 mg was used on days 1-4, Participants, randomised to start with CTR, received no interventions during the corresponding time period. After 3 weeks with PPX or CTR, respectively, all subjects completed a third PSG/EMG registration at home. PROM questionnaires were repeated and the TMI was established a second time by the same orofacial pain specialist (visit 3). Blood sampling was performed a second time for patients in the PPX group. Participants with CTR received PPX for 3 weeks, as described above, while medicated patients were allocated to CTR for the three ensuing weeks. The wash-out period was 3 weeks. A fourth, final PSG/EMG registration, identical to the previous ones, was completed by all subjects after the 3 weeks (visit 4), 6 weeks from baseline, together with a second physical examination. TMI was established and PROM questionnaires were applied. Blood sampling was repeated in participants who had been allocated to PPX during this sequence. Adverse events, reported undesirable symptoms and/or signs were collected on all visits. A single certified PSG technician, blinded to the study allocation, scored all the sleep studies, including respiratory and bruxism variables according to the American Academy of Sleep Medicine manual (Berry et al., 2012) . Elevated masseter EMG activity during sleep that reached at least twice the background activity for 0.25 s or more was scored as a bruxism burst. Bruxism bursts occurred in three possible versions or episodes. Elevations of masseter EMG activity were scored as phasic (brief) episodes if their duration was at least 0.25-2 s and at least three such elevations occurred in a regular sequence. A tonic (sustained) episode was scored if the duration of the EMG elevation was more than 2 s. Mixed episodes comprised both. The number of total episodes per hour was calculated and used as the main outcome variable. The number of phasic, tonic and mixed episodes per hour was also computed separately. Episodes could occur spontaneously or in conjunction with arousals, including those scored as respiratory events.
Statistical analyses
Statistical analyses were performed per protocol and also, for main variables, according to an intention-to-treat analysis (last observation carried forward). Period-adjusted P-values are given. A Mann-Whitney U-test was used to test differences between conditions for 13 subjects completing the protocol. Paired t-tests were used for parametric analyses for 18 subjects participating in the baseline registration. Spearman correlations were used to evaluate associations. Twotailed statistical analyses were performed at a significance level of P ≤ 0.05. A formal power analysis was not performed due to lack of previous data and the explorative purpose.
RESUL TS
Of the 20 subjects included in the study, from February 2012 to September 2013, 12 were men and eight were women. Seven subjects (three men and four women) terminated the study prematurely. Two drop-outs reported sleep problems and the remaining five withdrew consent for social reasons (Fig. 1) . Drop-outs after the habituation night or later (n = 6) did not differ significantly from those completing the study in terms of bruxism episodes per hour at baseline. For those completing the study, there was good adherence to the protocol.
Anthropometric data and dental attrition for the 13 participating subjects are given in Table 1 . Nine of the 13 participants fulfilled the criteria for at least one RDC/TMD diagnosis. Seven had myofascial pain, four had anterior disc displacement and two had arthralgia. The mean (SD) TMI was similar at baseline, PPX and CTR conditions; 0.17 (0.12), 0.13 (0.10) and 0.12 (0.10), respectively. Differences were not statistically significant.
The outcome variables are presented in Table 2 . The number of awakenings and percentage of awake time after sleep onset were higher after PPX compared with CTR (P = 0.03 and 0.02, respectively), suggesting sleep fragmentation. The proportion of rapid eye movement (REM) sleep was lower (P = 0.02) after PPX. Somewhat unexpectedly, PPX treatment was associated with a small reduction in the total apnea-hypopnea index (AHI; P = 0.05). Central sleep apnea was infrequent (data not shown).
Bruxism bursts and episodes (total, phasic, tonic and mixed) remained unchanged after PPX. Individual total bruxism episodes per hour are given in Fig. 2 . The differences, analysed parametrically, between the PPX and CTR conditions were not significant with respect to the number of bruxism bursts per hour (t = À1.78, P = 0.09), total episodes per hour (t = À1.38, P = 0.19), phasic episodes per hour (t = À1.79, P = 0.09), tonic episodes per hour (t = À0.29, P = 0.77) or mixed episodes per hour (t = À1.66, P = 0.12). Almost all bruxism episodes were associated with arousals, 91.2% at baseline, 92.2% after PPX and 93.9% during control condition.
Serum iron, serum total iron-binding capacity and serum transferrin were not correlated to bruxism variables at baseline. However, there was a trend towards a negative association between serum ferritin and the number of bruxism bursts per hour, r s = À0.46 (P = 0.06), total episodes per hour, r s = À0.41 (P = 0.09) and the number of phasic episodes per hour, r s = À0.41 (P = 0.08) (data not shown). There were no changes in routine clinical chemistry. None of the participants required any dose adjustment.
Periodic leg movements were infrequent, all patients but three had PLM indices 0 at baseline, and could not be evaluated in a meaningful statistical analysis. Sleepiness and quality of sleep data as evaluated by questionnaires are given in Table 3 (ESS, FOSQ, ISI, KSS and PSQI) and in Fig. 3 (MOS sleeping scale) . No differences were detected in any of these scales. Quality-of-life data obtained from the SF-36 questionnaire are given in Fig. 4 (for additional details, see supporting information). There were no treatment-related statistically significant differences. Sleep, respiratory and bruxism variables at baseline, after PPX and after control conditions, respectively, for the 13 participants who completed the protocol. P-values for differences between PPX and control conditions (adjusted for period) are also given. AHI, apnea-hypopnea index; mean sat, mean oxygen saturation during the night; PPX, pramipexole; REM, rapid eye movement. Numbers are given as the mean (standard deviation, SD) and the median (range). Italic numbers are significant p-values. Reported adverse events after PPX included nausea (n = 3), drowsiness (n = 3), poor sleep (n = 1) and blurred vision (n = 1). Two participants, one of whom had previously been diagnosed with RLS/WED, reported improved sleep. Adverse effects were mild and did not lead to the termination of medication.
DISCUSSION
Pramipexole is a D2 L and S, D3 and D4 receptor agonist with affinity to some serotonin and andrenergic receptors. PPX had no systematic effect on objectively assessed SB or the symptoms thereof. Comorbid sleep-disordered breathing General US populaƟon mean Baseline PPX Control Figure 3 . Patient-reported outcome (mean) for Sleep Scale from the Medical Outcome Study (MOS) at baseline, after pramipexole (PPX) and after control conditions, respectively, for the 13 participants who carried through the protocol. Reference values for a general US population (mean) are also given. All scales are scored from better (0) to worse (100), except for sleep adequacy, which is scored from worse (0) to better (100).
ª 2016 European Sleep Research Society was marginally reduced by PPX, the amount of REM sleep decreased and nocturnal awakenings were more frequent. The monitoring of iron-related biomarkers revealed a trend towards a negative association between serum ferritin and bruxism intensity. The aetiology of primary SB remains unknown, but a possible dysfunction of central dopamine mechanisms has been proposed (Mayer et al., 2015) . In fact, a recent publication suggested a common neurophysiological mechanism in both SB and PLM (Van Der Zaag et al., 2014) . However, it is unknown whether SB represents a homogeneous pathophysiological trait or whether there are in fact multiple phenotypic variants of the disorder. A previous study of the dopamine receptor agonist, bromocriptine, did not find any attenuation of SB, but studies with other dopamine agonists, such as PPX, were recommended (Lavigne et al., 2001,b) . The safety margin of PPX is not acceptable for treatment of SB with its mild health impact but the purpose of this study was explorative.
Participants in the current study were middle-aged and slightly overweight. They were otherwise healthy but a certain heterogeneity, for example, in AHI occurred. All fulfilled the criteria for 'probable' SB, according to recently published international consensus statements . Self-reported SB and a diagnosis based on clinical findings are known to have a low level of agreement (Paesani et al., 2013) . A diagnosis, according to the well-established criteria for RDC/TMD, was common among the participants, but 31% did not fulfil any of the criteria. Clinical signs, as judged by standardised orofacial examinations, performed by one specialist and summarised in TMI, were minor and did not change over time. As a result, the relationship between TMD and bruxism is complex (Manfredini and Lobbezoo, 2010; Raphael et al., 2012; Svensson et al., 2008) . However, SB can only be unequivocally detected by means of PSG recordings (Raphael et al., 2012) , and we therefore opted to quantify SB using EMG recordings. In addition, we opted to include a reasonably homogeneous, and established, group of patients with SB. All the study participants fulfilled the PSG diagnostic criteria for bruxism (Lavigne et al., 1996) on the baseline night. Grinding sounds, a further criterion, were not recorded, but the value of this symptom in defining bruxism has recently been questioned (Carra et al., 2015; Van Der Zaag et al., 2014) . The study participants were recruited from a pool of orofacial pain patients and not from the general population, which might have introduced a bias. They all participated without economic or other compensation. The percentage of drop-outs in the study was high, 35%. An analysis from the baseline night specifically addressing those with early study termination did not reveal any significant difference in demographic data or in variables related to bruxism.
However, many drop-outs reduce the power to detect possible changes induced by PPX. A post hoc analysis, based on the actual mean difference of 2.95 (7.02) episodes per hour in favour of control conditions, showed that 47 participants had resulted in a power of 0.80 at alpha 0.05. Thirty participants had resulted in a power of 0.60, 20 participants had resulted in a power of 0.43, and 10 participants in a power of 0.22 for the existing mean difference. Assuming a mean difference of 4.5 (7.02) episodes per hour implies that the included 20 participants had been enough for a power of 0.78. An assumed mean difference of 3.5 (7.02) episodes per hour requires 34 participants, and an assumed mean difference of 4.0 (7.02) 27 for a power of 0.80. Another limitation was that the population was not without comorbidity, for example, BMI and AHI, which also explains the lack of power.
There is a well-recognised natural variability in bruxism over time (Lavigne et al., 2001a; Van Der Zaag et al., 2008) , and the period of medication was therefore kept relatively short. The wash-out period after PPX, 3 weeks, was at baseline, after pramipexole (PPX) and after control conditions, respectively, for the 13 participants who carried through the protocol. As a reference, Swedish norms are also given. Higher scale scores mean better health. BP, bodily pain; GH, general health; MH, mental health; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.
ª 2016 European Sleep Research Society considered to be sufficient. Among recorded bruxism events, the phasic events dominated and almost all events were associated with arousals, in accordance with previous reports (Bader and Lavigne, 2000; Lavigne et al., 1996 Lavigne et al., , 2001a Macaluso et al., 1998) . Sleep organisation and macrostructure have previously been described as essentially normal in healthy individuals with SB (Bader and Lavigne, 2000; Lavigne et al., 1996; Macaluso et al., 1998) . The present findings were in line with these previous reports, although the administered dopaminergic medication may have caused a slight increase in sleep fragmentation, along with more frequent awakenings and shorter REM sleep duration. It is possible that these changes in sleep architecture alone may have caused the slight reduction in AHI in this study, in agreement with the effects reported after other medications with REM-reducing properties.
The current study suggests a possible association between low serum ferritin and a high intensity of certain bruxism variables, although this association did not reach the level of significance. Low serum ferritin and serum iron are common findings in patients with RLS/WED. Iron is recognised as an important co-factor for dopamine synthesis (Sun et al., 1998) , and iron supplementation provides a frequently used remedy in this condition. An association between iron metabolism and SB was previously unknown and, although not confirmed statistically in this study, the observation is certainly worthy of a future, more detailed epidemiological study.
It is concluded that the involvement of the dopamine system in bruxism is less likely, and the administration of the dopamine agonist, PPX, did not reduce either the intensity or the severity of nocturnal bruxism in patients with an established SB disorder.
